Clinical Trial Detail

NCT ID NCT03637803
Title MRx0518 and Pembrolizumab Combination Study
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors 4DPharma PLC
Indications

melanoma

lung non-small cell carcinoma

renal cell carcinoma

urinary bladder cancer

Therapies

MRx0518 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.